G
Goldfinch Biopharma
Singularly focused on discovering and developing precision therapies for patients with kidney disease
About Goldfinch Biopharma
Goldfinch Bio is a biotechnology company focused on developing precision therapies for patients with kidney diseases, particularly those with genetic origins. The company leverages advanced genomic data and cutting-edge research to identify and treat subgroups of patients with specific genetic markers. Operating in the biopharmaceutical sector, Goldfinch Bio primarily serves patients suffering from rare and complex kidney conditions. Its business model revolves around the research and development of novel drugs, which are then brought to market through clinical trials and regulatory approvals. Revenue is generated through the commercialization of these therapies, partnerships with other biotech firms, and potential licensing agreements. The company aims to transform the lives of patients by providing targeted treatments that address the underlying genetic causes of kidney diseases.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jun 2020 | $100M | $400M | Wellington Management · Casdin Capital · Schroder Adveq · Gilead Sciences | — |
| SERIES AOther financing | Dec 2016 | $55M | $220M | Third Rock Ventures | — |
Growth signals
Latest recorded traffic for Goldfinch Biopharma is 200 monthly website visits, down 81.8% over the last three months. Goldfinch Biopharma's team declined 28.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Goldfinch Biopharma in the Cambridge ecosystem
The Goldfinch Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
Third Rock Ventures
Eventide Asset Management
Wellington Management
Casdin Capital
Schroder Adveq
Gilead Sciences- IIIrving Investors
Yonjin Venture
BlackRock
Ally Bridge Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Goldfinch Biopharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Goldfinch Biopharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










